Phospholipid-mediated signaling systems as novel targets for treatment of heart disease.
The phospholipases associated with the cardiac sarcolemmal (SL) membrane hydrolyze specific membrane phospholipids to generate important lipid signaling molecules, which are known to influence normal cardiac function. However, impairment of the phospholipases and their related signaling events may be contributory factors in altering cardiac function of the diseased myocardium. The identification of the changes in such signaling systems as well as understanding the contribution of phospholipid-signaling pathways to the pathophysiology of heart disease are rapidly emerging areas of research in this field. In this paper, I provide an overview of the role of phospholipid-mediated signal transduction processes in cardiac hypertrophy and congestive heart failure, diabetic cardiomyopathy, as well as in ischemia-reperfusion. From the cumulative evidence presented, it is suggested that phospholipid-mediated signal transduction processes could serve as novel targets for the treatment of the different types of heart disease.
Tappia
Paramjit S
PS
Institute of Cardiovascular Sciences, St. Boniface General Hospital Research Centre and Department of Human Nutritional Sciences, University of Manitoba, Winnipeg, MB, R2H 2A6, Canada.
D000818:Animals; D006332:Cardiomegaly / Q000188:drug therapy / Q000378:metabolism; D009202:Cardiomyopathies / Q000188:drug therapy / Q000378:metabolism; D002317:Cardiovascular Agents / Q000494:pharmacology* / Q000627:therapeutic use; D048909:Diabetes Complications / Q000188:drug therapy / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D006331:Heart Diseases / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D006333:Heart Failure / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D015428:Myocardial Reperfusion Injury / Q000188:drug therapy / Q000378:metabolism; D009206:Myocardium / Q000378:metabolism; D010740:Phospholipases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D010743:Phospholipids / Q000378:metabolism*; D012508:Sarcolemma / Q000187:drug effects / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects*
D002317:Cardiovascular Agents; D004791:Enzyme Inhibitors; D010743:Phospholipids; D010740:Phospholipases